BioCentury
ARTICLE | Clinical News

Vevesca: Pivotal

February 20, 2001 8:00 AM UTC

OGS said preliminary analysis of a six-month, 36-patient pivotal study showed Vevesca oral N-butyldeoxynojirimycin glucosyltransferase inhibitor alone successfully maintained Gaucher disease patients ...